Torthaí cuardaigh - Jason Gotlib

Beachtaigh na torthaí
  1. 1
    Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

    Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation de réir Jason Gotlib

    Foilsithe / Cruthaithe 2005
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    How I treat atypical chronic myeloid leukemia

    How I treat atypical chronic myeloid leukemia de réir Jason Gotlib

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    World Health Organization‐defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management de réir Jason Gotlib

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management de réir Jason Gotlib

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management de réir Jason Gotlib

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    World Health Organization‐defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management de réir Jason Gotlib

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Myeloid neoplasms with eosinophilia

    Myeloid neoplasms with eosinophilia de réir Andreas Reiter, Jason Gotlib

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management de réir William Shomali, Jason Gotlib

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management

    World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management de réir William Shomali, Jason Gotlib

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management de réir William Shomali, Jason Gotlib

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update

    Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update de réir Ayalew Tefferi, Jason Gotlib, Animesh Pardanani

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

    New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis de réir Andreas Reiter, Tracy I. George, Jason Gotlib

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

    The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment de réir Jason Gotlib, Julia E. Maxson, Tracy I. George, Jeffrey W. Tyner

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management de réir Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    Foilsithe / Cruthaithe 2003
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

    Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations de réir Robert S. Ohgami, Lisa Ma, Jason D. Merker, Jason Gotlib, Iris Schrijver, James L. Zehnder, Daniel A. Arber

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in <i>Caenorhabditis elegans</i> and <i>Homo sapiens</i>

    Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in <i>Caenorhabditis elegans</i> and <i>Homo sapiens</i> de réir Massa J. Shoura, Idan Gabdank, Loren Hansen, Jason D. Merker, Jason Gotlib, Stephen D. Levene, Andrew Fire

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    The serum tryptase test: an emerging robust biomarker in clinical hematology

    The serum tryptase test: an emerging robust biomarker in clinical hematology de réir Peter Valent, Wolfgang R. Sperr, Karl Sotlar, Andreas Reiter, Cem Akin, Jason Gotlib, Hans-Peter Horny, Michel Arock

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia de réir James Scott McClellan, Holbrook E. Kohrt, Steven Coutré, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation.

    Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. de réir William Wallace, Stephen T. Ahlers, Jason Gotlib, Valentin Bragin, J. Sugár, R Gluck, Paul Shea, Keith L. Davis, Vahram Haroutunian

    Foilsithe / Cruthaithe 1993
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

    Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I de réir Ruben A. Mesa, Srđan Verstovšek, Vikas Gupta, John Mascarenhas, Ehab Atallah, Timothy C. Burn, William Sun, Victor Sandor, Jason Gotlib

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: